LDL-C management: should it begin in the cathlab?

Sponsored by Amgen

Anchorperson: G. Montalescot

Discussants: B. Bergmark, C. Rogers

Summary

This EuroPCR 2026 session examines the evolving role of LDL cholesterol management in patients undergoing percutaneous coronary intervention (PCI), with a focus on the potential benefits of initiating intensive lipid-lowering strategies early in the patient pathway.

The discussion reviews emerging evidence on PCSK9 inhibition in elective PCI patients without prior myocardial infarction or stroke, and considers the implications for contemporary clinical practice. Particular attention is also given to the growing body of data supporting rapid and intensive LDL-C reduction in acute coronary syndrome (ACS).

In parallel, the session explores how advanced imaging and artificial intelligence-enabled platforms, including HeartFlow, may contribute to earlier risk stratification and more personalised management of high-risk atherosclerotic cardiovascular disease (ASCVD).

Learning Objectives

To discuss the latest evidence on PCSK9 inhibition in patients undergoing elective PCI and its implications for clinical practice
To assess current and emerging data supporting early and intensive LDL-C management in ACS
To examine how advanced imaging and artificial intelligence-enabled platforms, including HeartFlow, can enhance early risk stratification and optimise management of high-risk ASCVD

Speaker

B. Bergmark

Impact of PCSK9 inhibition in patients with prior PCI (without prior MI/stroke)

Download presentation